Listen to this article

The battle for Botox maker Allergan Inc. appears to be over — and the winner is not Bridgewater-based Valeant Pharmaceuticals, but a different New Jersey company.Actavis PLC, which has its U.S. headquarters in Parsippany, will pay $66 billion in cash and stock for the California-based company, according to a news release the two firms issued Monday.

“This acquisition creates the fastest-growing and most dynamic growth pharmaceutical company in global health care, making us one of the world’s top 10 pharmaceutical companies,” Brent Saunders, CEO and president of Actavis, said in the release. “… This is a financially compelling transaction. With pro forma revenues in excess of $23 billion anticipated in 2015, this combination doubles the revenue generated by our brands business and doubles the international revenue of the combined company. Management is committed to maximizing the potential for the combined company to drive industry-leading top- and bottom-line growth.”

Click here to subscribe to the NJBIZ e-newsletters

Actavis will pay $129.22 in cash and 0.3683 shares in stock for each share of Allergan common stock, the companies said. That would value Allergan at $219 per share, based on Friday’s closing prices. Both boards of directors have approved the deal, the companies added.

The Actavis offer trumped the hostile takeover bid Valeant made in April, which was valued at approximately $50 billion at the time. Valeant was willing to pay as much as $200 per share as late as October, according to published reports.

Valeant, which just moved its headquarters to Bridgewater, will not challenge the deal, it said in its own statement.

“We have seen the announcement that Allergan and Actavis have made, and while we will review any such agreement in determining our course of action, Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan,” J. Michael Pearson, chairman and CEO of Valeant, said in the statement. “… We will remain focused on delivering strong organic results and evaluating acquisition opportunities as we always have: prudently, in a disciplined manner, and in the best interests of our shareholders.”

Saunders will lead the combined company, with Actavis Chairman Paul Bisaro remaining in that role, the companies said. Both companies’ senior management teams will be involved in the integration process, they added.

Actavis also wrapped up another deal Monday, finalizing its $675 million tender offer for Chicago-based drugmaker Durata Therapeutics Inc.

ALSO ON NJBIZ:

Christie chief of staff O’Dowd to leave for Cooper executive role

Editorial: High-priced flight — Poll paints discouraging picture

Amid growing alarm in Atlantic City, monthly revenue report is a mixed bag for casinos